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X-chromosome inactivation equalises the dosage of
X-linked genes in XX females with that in XY males.
Recent findings reveal that the BRCA1 breast cancer
susceptibility gene has an important function in this
epigenetic phenomenon.
Increasingly, scientific research focuses on ever more
discrete problems but biology tends to transcend
such oversimplification. There could be no better
example of this than the recent demonstration that the
BRCA1 breast cancer susceptibility gene plays a role
in X-chromosome inactivation [1]. Equality of dosage
of X-linked genes between XY males and XX females
in mammals is achieved by inactivation of one of the
two X chromosomes in each somatic female cell [2].
XIST is critical for this process but little is known
about how the product of this gene, a non-coding
RNA molecule, mediates the silencing of an entire
chromosome [2]. In particular, accessory proteins
important for this process have not been identified.
Now, in a surprising new development, the BRCA1
protein has been shown to be crucial for silencing the
X chromosome [1].
X-inactivation takes place early in embryogenesis
and can be arbitrarily divided into a series of events;
counting and choice, initiation, propagation and
maintenance of the inactive state [2]. Initiation begins
with the stabilisation of transcripts from the XIST
gene on the future inactive X chromosome (Xi), with
which they remain associated in cis. Subsequently,
this X chromosome acquires features of constitutive
heterochromatin: late replication, histone H3 lysine 9
methylation (H3mK9), hypoacetylation of histone H4
and the methylation of CpG islands [2,3]. Additionally,
the variant histone macroH2A1 (mH2A1) becomes
concentrated on Xi [2–4]. These layers of epigenetic
modification appear to act synergistically [4] and are
directed by an as yet unknown mechanism, which
presumably requires multiple proteins. This hard-
wiring of the silenced state of the Xi is maintained
through subsequent cell divisions and is highly resis-
tant to reactivation [2].
Heterozygous carriers of mutations in BRCA1 are at
very significantly elevated risk of early onset breast
and ovarian cancer [5,6]. The loss of the single wild-
type allele in cancers of BRCA1 mutation carriers indi-
cates that BRCA1 falls into the category of tumour
suppressor genes but how loss of BRCA1 function
leads to tumourigenesis is still unclear. BRCA1 has
been implicated in a wide range of cellular processes
including DNA damage repair and cell cycle check-
point activation. Considerable evidence also indicates
a role for BRCA1 in transcriptional regulation [5,6].
BRCA1 is present in a variety of multiprotein com-
plexes involved in DNA repair, transcription and chro-
matin remodeling. In these processes it may act, at
least in part, as a scaffolding protein or as a regulator
of protein stability via its RING finger motif which has
ubiquitin ligase activity [5].
Livingston and colleagues [1] have now shown that
there is a relationship between BRCA1 and X-inactiva-
tion (Figure 1). Immunofluorescence analysis revealed
that, in a subset of female cells, XIST RNA co-localised
with BRCA1 presumably reflecting an interaction
(either direct or indirect) between the two molecules.
This observation was supported by biochemical analy-
sis. However, in tumours and cell lines lacking wild-
type BRCA1, XIST failed to form Xi-associated foci.
Other markers of the Xi such as H3mK9, mH2A1 incor-
poration and asynchronous replication of the two X
chromosomes were also missing in the absence of
functional BRCA1. These phenotypic indicators of loss
of X-inactivation were accompanied by apparent reac-
tivation of transcription from Xi as measured by an
increase in the expression of an X-linked gene. Strong
evidence for the critical role of BRCA1 in the X-inacti-
vation process was provided by two observations.
First, depletion of BRCA1 using RNA interference was
accompanied by the loss of Xi-associated XIST foci.
Second, reconstitution of a BRCA1 mutant cell line
with wild-type BRCA1 led to the reformation of XIST
foci in the majority of cells.
Independent support for a function for BRCA1 in
keeping the Xi silent has come from tumour gene
expression microarray data [7]. Comparison of
BRCA1-associated ovarian tumours with those arising
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Figure 1. Schematic representation of the effect of loss of
BRCA1 on the characteristics of the inactive X chromosome.
The inactive X chromosome is visible as the Barr body and
associated with XIST RNA. Other features of the inactive X
include modification of histone H3 by methylation on lysine 9
(H3mK9) and incorporation of the variant histone mH2A1. These
features are lost with loss of BRCA1 function (BRCA1–/–). 
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sporadically or as a consequence of BRCA2 mutation
revealed the overexpression of six X-linked genes in
the BRCA1 tumours compared with the other two
groups. This is consistent with the reactivation of a
previously inactive Xi in the BRCA1 tumours. The
finding of differential expression of these X-chromo-
somal genes between BRCA1- and BRCA2-associ-
ated ovarian cancers is relevant, because BRCA2 had
no effect on the localisation of XIST domains and
seems not to be important for X-inactivation [1].
Dosage compensation systems, of which X-inacti-
vation is one type, appear to have evolved indepen-
dently in many animal species that have hetero-
morphic sex chromosomes [8]. For example, in
Drosophila, dosage compensation results in two-fold
upregulation of the single X chromosome in males
instead of the inactivation of a single X in females, as
occurs in mammals. Despite this, there are some sim-
ilarities between the Drosophila dosage compensation
system and mammalian X-inactivation systems.
Importantly, in both systems, non-coding RNAs (Rox
and XIST) are critical to the process (Table 1). Both
BRCA1 and a binding partner BARD1 are RING-
domain-containing proteins that may be functionally
analogous to the RING proteins MSL2 and MOF, com-
ponents of the Drosophila dosage compensation
complex [9,10]. Furthermore, BRCA1 interacts with
RNA helicase A, the mammalian orthologue of MLE.
Given these striking comparisons it would be interest-
ing to know whether these and other BRCA1-interact-
ing proteins are also involved in X-inactivation. This
might reflect a broader role for BRCA1 in regulating
heterochromatin in general rather than in X-inactiva-
tion specifically. If this is the case there will be signif-
icant implications for the tumour suppressor function
of BRCA1.
These new data reveal a novel link between X-chro-
mosome activity and cancer. Furthermore, it might
provide a mechanistic framework for understanding
some pieces of evidence that have previously sug-
gested this connection. These come from three areas
of study: the Barr body, Klinefelter’s syndrome and
non-random inactivation. First, the Barr body (the
cytologically visible Xi) was found to be reduced in fre-
quency in breast cancers compared with normal
tissue [11] and this was associated with poor progno-
sis [12]. Second, breast cancer occurs only rarely in
men but a 47, XXY genotype (Klinefelter’s syndrome)
confers a 50-fold increased risk compared with XY
men [13]. However, this seems likely to be associated
with hormonal dysfunction rather than the presence of
two X chromosomes particularly as 47, XXX women
have no increased risk [14]. Third, the normal random
nature of X-inactivation appears to be altered in
BRCA1 mutation carriers that are susceptible to
cancer [15,16].
The exact mechanism whereby reactivation of the Xi
might influence tumourigenic progression is yet to be
clarified. Nevertheless, the new role for BRCA1 in
silencing the X chromosome is likely to open up excit-
ing avenues of investigation in both cancer research
and the epigenetic regulation of gene expression.
References
1. Ganesan, S., Silver, D.P., Greenberg, R.A., Avni, D., Drapkin, R.,
Miron, A., Mok, S.C., Randrianarison, V., Brodie, S., Salstron, J. et
al. (2002). BRCA1 supports XIST RNA concentration on the inactive
X chromosome. Cell 111, 393–405.
2. Plath, K., Mlynarczyk-Evans, S., Nusinow, D.A. and Panning, B.
(2002). Xist RNA and the mechanism of X chromosome inactivation.
Annu. Rev. Genet. 36, 233–278.
3. Heard, E., Rougeulle, C., Arnoud, D., Avner, P., Allis, D. and Spector,
D.L. (2001). Methylation of histone H3 at Lys-9 is an early mark on
the X chromosome during X inactivation. Cell 107, 727–738.
4. Csankovszki, G., Nagy, A. and Jaenisch, R. (2001). Synergism of
Xist RNA, DNA methylation and histone hypoacetylation in main-
taining X chromosome inactivation. J. Cell Biol. 153, 773–783.
5. Kerr, P. and Ashworth, A. (2001). New complexities for BRCA1 and
BRCA2. Curr. Biol. 11, R668–R676.
6. Venkitaraman, A.R. (2002). Cancer susceptibility and the functions
of BRCA1 and BRCA2. Cell 108,171–182.
7. Jazaeri, A.A., Yee, C.J., Sotiriou, C., Brantley, K.R., Boyd, J. and Liu,
E.T. (2002). Gene expression profiles of BRCA1-linked, BRCA2-
linked and sporadic ovarian tumours. J. Natl. Cancer Inst. 94,
990–1000.
8. Marin, I., Siegal, M.L. and Baker, B.S. (2000). The evolution of
dosage-compensation mechanisms. Bioessays 22, 1106–1114.
9. Copps, K., Richman, R., Lyman, l.M., Chang, K.A., Rampersad-
Ammons, J. and Kuroda, M.I., (1998). Complex formation by the
Drosophila MSL proteins: role of the MSL2 RING finger in protein
complex assembly. EMBO J. 17, 5409–5417.
10. Akhtar, A. and Becker, P.B. (2000). Activation of transcription
through histone H4 acetylation by MOF, an acetyltransferase essen-
tial for dosage compensation in Drosophila. Mol. Cell 5, 367–375.
11. Kimel, V.M. (1957). Clinical-cytological correlations of mammary
carcinoma based upon sex-chromatin counts. Cancer 10, 922–927.
12. Rajeswari, S., Ghosh, S.N., Shah, P.M. and Borah, V.J. (1977). Barr
body frequency in the human breast cancer tissue. Eur. J. Cancer
13, 99–102.
13. Giordano, S.H., Buzdar, A.U. and Hortobagyi, G.N. (2002). Breast
cancer in men. Annals of Int. Med. 137, 678–687.
14. Spiers, A.S. and Turner, J.E. (1977). Sex chromatin in women with
breast cancer, leukemia, lymphoma and hypertension. JAMA 238,
1812–1813.
15. Buller, R.E., Sood, A.K., Lallas, T., Buekers, T. and Skilling, J.S.
(1999). Association between non-random X-chromosome inactiva-
tion and BRCA1 mutation in germline DNA of patients with ovarian
cancer. J. Natl. Cancer Inst. 91, 339–346.
16. Kristiansen, M., Langerod, A., Knudson, G.P., Weber, B.L., Borre-
sen-Dale, A.-L. and Orstavik, K.H. (2002). High frequency of skewed




Table 1. Potential mammalian equivalents of components of the
Drosophila dosage compensation system.
Mammals Function/Features Drosophila
XISTa Non-coding RNAs rox1, rox2
essential for dosage 
compensation
BRCA1a Acidic domain, msl1
BRCA1a, BARD1a RING domain msl2
MSL3-L1b Chromodomain msl3
RNA helicase Ab, Helicase, ATPase mle
BACH1a
MOFb HAT, RING domain mof
Genes in bold are known to affect dosage compensation. a Genes
that may have a similar function to Drosophila genes. BRCA1 inter-
acts with BARD1, RNA helicase A and BACH1. b Known mammalian
orthologues of Drosophila compensation genes.
